BOCA RATON, Fla., Jan. 11 /PRNewswire-FirstCall/ -- Breckenridge
Pharmaceutical, Inc. announced today that it settled "Paragraph IV"
litigation with Novartis concerning Trileptal(R) and that the U.S. Food and
Drug Administration approved Breckenridge's Abbreviated New Drug
Application for oxcarbazepine 150mg, 300mg and 600 mg tablets in the United
States ("Oxcarbazepine Tablets").
Breckenridge enjoys a shared 180-day exclusivity period and will
immediately launch Oxcarbazepine Tablets 150 mg, 300 mg, and 600 mg.
Oxcarbazepine Tablets are AB rated to Trileptal(R), a $600 million brand
name drug marketed by Novartis Pharmaceuticals Corporation, and are used in
Breckenridge is actively seeking development and marketing alliances
with domestic and foreign companies for generic and branded
Breckenridge products are contract manufactured through partnerships
with pharmaceutical manufacturers in state-of-the-art facilities throughout
the U.S. Breckenridge maintains a stringent Quality Assurance program to
ensure a consistent supply of quality pharmaceutical products.
Breckenridge Pharmaceutical, Inc., a privately-held pharmaceutical
marketing research and development company founded in 1983, is
headquartered in Boca Raton, FL, with offices in Berlin, CT, and Fairfield,
NJ. Breckenridge markets over 100 products in many therapeutic categories
to over 100 customers in all classes of trade.
Trileptal(R) is a registered trademark of Novartis Pharmaceuticals
SOURCE Breckenridge Pharmaceutical, Inc.